SG Talk

Covid-19 vaccines currently on the market in Europe are based on either adenoviral vectors, including vaccines from AstraZeneca and Johnson & Johnson, or newer messenger mRNA (mRNA) technology including vaccines from BioNTech/Pfizer and Moderna. Their exclusive target is the spike protein on the surface of the virus, which the virus uses to enter cells. However, the protein mutates much more quickly than other parts of the virus, which increases the likelihood of the virus becoming resistant to the vaccine.

Inactivated vaccines like Valneva’s candidate allow the immune system to target a wider range of viral proteins than approved vaccines, which could make them harder for the virus to resist.

According to Valneva’s phase III results, those given Valneva’s vaccine had the same risk of Covid-19 infection as those given AstraZeneca’s vaccine, and there were no severe cases in either group. However, this trial differed from those of BioNTech/Pfizer and other Covid-19 vaccine frontrunners by focusing on proxy measures such as blood antibody levels as its main success indicator rather than the number of infection cases. Many scientists consider these to be satisfactory surrogate endpoints for emergency authorization.

https://www.labiotech.eu/trends-news/val...9-vaccine/

The endpoint is the number of infected cases v high antibody levels but still infected.

Inactivated vaccines have the potential to provide an added benefit by boosting T-cell responses against additional SARS-CoV-2 proteins.

Bump.